Loading
Loading…
Loading…
| # | Company | Amount | Rank | Status |
|---|---|---|---|---|
| 1 | H1₹43.57Admitted-Finance | ₹43.57 | H1 | Admitted-Finance |
| 2 | H2₹41.96−₹1.61 (3.70%)Admitted-Finance | ₹41.96−₹1.61 (3.70%) | H2 | Admitted-Finance |
| 3 | Rejected-Technical SURVEY NO 144 A JAROD SAMLAYA ROAD VILL HARIPURA TAL SAVLI DIST VADODARA GUJARAT INDIA 391520 | VADODARA | VADODARA | GUJARAT | 391520 | - | - | Rejected-Technical As per Evaluation Summary. |
| 4 | Rejected-Technical | - | - | Rejected-Technical As per Evaluation Summary. |
| Sl No | Description | Qty | Unit | Mylan Laboratories Limited H1 | HETERO LABS LIMITED H2 |
|---|---|---|---|---|---|
| 1.00ANTI TB DRUGS | |||||
| 1.01 | Sofosbuvir 400mg | 45,51,120 | Tablets | 31.15 ₹34.89 Lowest | 31.25 ₹35 |
| 1.02 | Daclatasvir 60mg | 45,51,120 | Tablets | 7.75 ₹8.68 | 6.21 ₹6.96 Lowest |
Tender Value
Refer Docs
EMD Value
₹2.9 L
Closing Date
18 Apr 2024, 3:00 pmClosed
DG and CEO CMSS New Delhi
CMSS New Delhi
Tender for Procurement of Sofosbuvir 400mg and Daclatasvir 60mg for NVHCP
2024_CMSS_801620_1
CMSS/PROC/2023-24/NVHCP/062
Open Tender
Drugs and Pharmaceutical Products
Supply
60 days
CMSS New Delhi
As per tender
2 documents required · 2 mandatory
₹0
₹2.9 L
Yes
CMSS New Delhi
14 May 2024
20 Mar 2024
19 Apr 2024
20 Mar 2024
18 Apr 2024
20 Mar 2024
20 Mar 2024 - 22 Mar 2024
22 Mar 2024
ANTI TB DRUGS
Sofosbuvir 400mg
Daclatasvir 60mg
HETERO LABS LIMITED
HETERO LABS LIMITED
stage.html
html • 0.03 MB
tech_eval.pdf
boq_comp_chart.xlsx
xlsx
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
details.html
html • 0.03 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .